Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-β receptor in vascular smooth muscle cells

Cell Mol Life Sci. 2022 Feb 5;79(2):121. doi: 10.1007/s00018-022-04159-8.

Abstract

Toll-like receptors (TLRs) recognise pathogen‑associated molecular patterns, which allow the detection of microbial infection by host cells. Bacterial-derived toxin lipopolysaccharide activates TLR4 and leads to the activation of the Smad2 transcription factor. The phosphorylation of the Smad2 transcription factor is the result of the activation of the transforming growth factor-β receptor 1 (TGFBR1). Therefore, we sought to investigate LPS via TLR4-mediated Smad2 carboxy terminal phosphorylation dependent on the transactivation of the TGFBR1. The in vitro model used human aortic vascular smooth muscle cells to assess the implications of TLR4 transactivation of the TGFBR1 in vascular pathophysiology. We show that LPS-mediated Smad2 carboxy terminal phosphorylation is inhibited in the presence of TGFBR1 inhibitor, SB431542. Treatment with MyD88 and TRIF pathway antagonists does not affect LPS-mediated phosphorylation of Smad2 carboxy terminal; however, LPS-mediated Smad2 phosphorylation was inhibited in the presence of MMP inhibitor, GM6001, and unaffected in the presence of ROCK inhibitor Y27632 or ROS/NOX inhibitor DPI. LPS via transactivation of the TGFBR1 stimulates PAI-1 mRNA expression. TLRs are first in line to respond to exogenous invading substances and endogenous molecules; our findings characterise a novel signalling pathway in the context of cell biology. Identifying TLR transactivation of the TGFBR1 may provide future insight into the detrimental implications of pathogens in pathophysiology.

Keywords: Smad; Transactivation dependent; Transforming growth factor beta.

MeSH terms

  • Benzamides / pharmacology
  • Cell Line
  • Dioxoles / pharmacology
  • Humans
  • Lipopolysaccharides / pharmacology*
  • Matrix Metalloproteinase 2 / metabolism
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / metabolism
  • Myeloid Differentiation Factor 88 / metabolism
  • Phosphorylation
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism
  • Receptor, Transforming Growth Factor-beta Type I / genetics
  • Receptor, Transforming Growth Factor-beta Type I / metabolism*
  • Smad2 Protein / metabolism
  • Toll-Like Receptor 4 / metabolism*
  • Transcriptional Activation / drug effects*
  • Up-Regulation / drug effects

Substances

  • 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide
  • Benzamides
  • Dioxoles
  • Lipopolysaccharides
  • Myeloid Differentiation Factor 88
  • Plasminogen Activator Inhibitor 1
  • Smad2 Protein
  • Toll-Like Receptor 4
  • Receptor, Transforming Growth Factor-beta Type I
  • Matrix Metalloproteinase 2